NASDAQ · VTVT
vTv Therapeutics Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VTVT: Nov 5, 2026
vTv Therapeutics Inc. Class A Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.07. The reported EPS for the same quarter last year was $-1.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.07 | $-1.01 | $-1.13 | 2 |
| Dec 2026 | $-1.14 | $-0.89 | $-1.45 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Zacks · Fintel- MarketBeat · Oct 20, 8:02 PM EDTvTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 HypoglycemiaPromising Upsides on these Biotech Penny StocksvTv Therapeutics (NASDAQ:VTVT) used a virtual key opinion leader event to outline the continuing burden of hypoglycemia in type 1 diabetes, present patient and physician market-research findings, and review the development program fo
- RTTNews · Oct 8, 1:22 AM EDTVTv's HPPD Receives FDA Orphan Drug Status For Sickle Cell Disease(RTTNews) – Wednesday, vTv Therapeutics Inc. (VTVT) said that the U.S. FDA granted Orphan Drug Status to HPPD (HPP8668) for the treatment of sickle cell disease.
- Zacks · May 15, 8:55 AM EDTvTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be SustainableIf you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therapeutics (VTVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- Zacks · Apr 20, 9:55 AM EDTWall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Apr 2, 9:55 AM EDTWall Street Analysts Think vTv Therapeutics (VTVT) Could Surge 31.58%: Read This Before Placing a BetThe mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Mar 17, 9:55 AM EDTWall Street Analysts Believe vTv Therapeutics (VTVT) Could Rally 39.86%: Here's is How to TradeThe average of price targets set by Wall Street analysts indicates a potential upside of 39.9% in vTv Therapeutics (VTVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- Fintel · Mar 12, 8:03 PM EDTEvercore ISI Group Initiates Coverage of vTv Therapeutics (VTVT) with Outperform RecommendationFintel reports that on March 12, 2026, Evercore ISI Group initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Outperform recommendation. Analyst Price Forecast Suggests 55.01% Upside
- RTTNews · Mar 11, 4:27 AM EDTVTv Therapeutics Posts Wider FY25 Loss, Advances Phase 3 CATT1 Trial For Type 1 Diabetes(RTTNews) – vTv Therapeutics Inc. (VTVT) reported fourth-quarter and full-year 2025 financial results and outlined continued progress across its late-stage diabetes pipeline, led by, Cadisegliatin the company's oral, liver-selective glucokinase activator being developed as an adj
- Fintel · Jan 23, 7:03 AM ESTRoth Capital Initiates Coverage of vTv Therapeutics (VTVT) with Buy RecommendationFintel reports that on January 23, 2026, Roth Capital initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy recommendation. Analyst Price Forecast Suggests 43.69% Upside
- Fintel · Jan 14, 5:44 AM ESTvTv Therapeutics (VTVT) Price Target Increased by 16.19% to 48.20The average one-year price target for vTv Therapeutics (NasdaqCM:VTVT) has been revised to $48.20 / share. This is an increase of 16.19% from the prior estimate of $41.48 dated December 18, 2025. The price target is an average of many targets provided by analy
- Fintel · Jan 5, 7:04 PM ESTTD Cowen Initiates Coverage of vTv Therapeutics (VTVT) with Buy RecommendationFintel reports that on January 5, 2026, TD Cowen initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy recommendation. Analyst Price Forecast Suggests 2.59% Downside
- Zacks · Dec 24, 12:00 PM ESTvTv Therapeutics (VTVT) Upgraded to Buy: Here's What You Should KnowvTv Therapeutics (VTVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for vTv Therapeutics Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.